文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症患者中的五聚素-3、肌钙蛋白T与N末端B型利钠肽原

Pentraxin-3, Troponin T, N-Terminal Pro-B-Type Natriuretic Peptide in Septic Patients.
PubMed 文献 · Shock · 2020-01-01
一句话结论脓毒症患者中五聚素-3、肌钙蛋白T与N末端B型利钠肽原均异常升高,N末端B型利钠肽原升高与90天死亡率关联最强。

该研究为对白蛋白意大利结局脓毒症数据库子集的回顾性分析,纳入40个意大利重症监护病房的958例脓毒症患者,患者来自比较白蛋白替代加晶体液与单用晶体液的随机临床试验。入院第1、2、7天检测五聚素-3、肌钙蛋白T与N末端B型利钠肽原水平。五聚素-3在100%、肌钙蛋白T在84.5%、N末端B型利钠肽原在93.4%的953例患者中异常升高,三者均从第1天至第7天下降。五聚素-3随乳酸水平升高而单调升高,肌钙蛋白T在中心静脉血氧饱和度低于70%时显著更高,N末端B型利钠肽原随乳酸和液体平衡升高而升高,且其升高与90天死亡率关联最强。

要点

  • 脓毒症患者中五聚素-3(71.8 [32.9-186.3] ng/mL)、肌钙蛋白T(50.4 [21.6-133.6] ng/L)、N末端B型利钠肽原(4,393 [1,313-13,837] ng/L)在100%、84.5%、93.4%的953例患者中异常升高。
  • 五聚素-3随乳酸水平升高而单调升高,提示其与脓毒症严重程度相关。
  • 肌钙蛋白T在中心静脉血氧饱和度低于70%时显著高于中心静脉血氧饱和度较高时,提示氧输送受损。
  • N末端B型利钠肽原随乳酸和液体平衡升高而升高,且在中心静脉血氧饱和度低于70%时更高,提示与脓毒症严重程度、氧输送及积极液体策略相关。
  • N末端B型利钠肽原升高与90天死亡率关联最强。

适用人群与场景

  • 纳入白蛋白意大利结局脓毒症数据库子集中的958例脓毒症患者,来自40个意大利重症监护病房,均参与比较白蛋白替代加晶体液与单用晶体液的随机临床试验。

研究设计与关键结果

  • 研究类型为对白蛋白意大利结局脓毒症数据库子集的回顾性分析,纳入958例脓毒症患者,来自40个意大利重症监护病房,患者来自比较白蛋白替代加晶体液与单用晶体液的随机临床试验。
  • 五聚素-3和肌钙蛋白T在两个治疗组间非常相似,而N末端B型利钠肽原在白蛋白治疗组几乎翻倍。
  • 五聚素-3(71.8 [32.9-186.3] ng/mL)、肌钙蛋白T(50.4 [21.6-133.6] ng/L)、N末端B型利钠肽原(4,393 [1,313-13,837] ng/L)在953例患者中分别有100%、84.5%、93.4%异常升高,三者均从第1天至第7天下降。
  • 五聚素-3随乳酸水平升高而单调升高;肌钙蛋白T在中心静脉血氧饱和度低于70%时显著高于中心静脉血氧饱和度较高时;N末端B型利钠肽原随乳酸和液体平衡升高而升高,在中心静脉血氧饱和度低于70%时高于中心静脉血氧饱和度较高时,但即使在中心静脉血氧饱和度较高时N末端B型利钠肽原仍显著升高。
  • N末端B型利钠肽原升高与90天死亡率关联最强。

证据类型、等级与局限

  • 证据类型为对随机临床试验数据库的回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在脓毒症患者中,五聚素-3、肌钙蛋白T与N末端B型利钠肽原均异常升高且从第1天至第7天下降,检测这些生物标志物可能有助于评估脓毒症严重程度、氧输送/利用障碍及液体策略,但原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the behavior of pentraxin-3 (PTX3), troponin T (hsTnT), N-terminal pro-B type Natriuretic Peptide (NT-proBNP) in sepsis and their relationships with sepsis severity and oxygen transport/utilization impairment.

DESIGN: Retrospective analysis of PTX3, hsTnT, NT-proBNP levels at day 1, 2, and 7 after admission in the intensive care unit in a subset of the Albumin Italian Outcome Sepsis database.

SETTING: Forty Italian intensive care units.

PATIENTS: Nine hundred fifty-eight septic patients enrolled in the randomized clinical trial comparing albumin replacement plus crystalloids and crystalloids alone.

INTERVENTIONS: The patients were divided into sextiles of lactate (marker of severity), ScvO2 (marker of oxygen transport), and fluid balance (marker of therapeutic strategy).

MEASUREMENTS AND MAIN RESULTS: PTX3 and hsTnT were remarkably similar in the two treatment arms, while NT-proBNP was almost double in the albumin treatment group. However, as the distribution of all these biomarkers was similar between control and treatment arms, for the sake of clarity, we analyzed the patients as a single cohort. PTX3 (71.8 [32.9-186.3] ng/mL), hsTnT (50.4 [21.6-133.6] ng/L), and NT-proBNP (4,393 [1,313-13,837] ng/L) were abnormally elevated in 100%, 84.5%, 93.4% of the 953 patients and all decreased from day 1 to day 7. PTX3 monotonically increased with increasing lactate levels. The hsTnT levels were significantly higher when ScvO2 levels were abnormally low (< 70%), suggesting impaired oxygen transport compared with higher ScvO2 levels, suggesting impaired oxygen utilization. NT-proBNP was higher with higher lactate and fluid balance. At ScvO2 levels < 70%, the NT-proBNP was higher than at higher ScvO2 levels. However, even with higher ScvO2, the NT-proBNP was remarkably elevated, suggesting volume expansion. Increased level of NT-proBNP showed the strongest association with 90-day mortality.

CONCLUSIONS: The selected biomarkers seem related to different mechanisms during sepsis: PTX3 to sepsis severity, hsTnT to impaired oxygen transport, NT-proBNP to sepsis severity, oxygen transport, and aggressive fluid strategy.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Vassalli F, Masson S, Meessen J, et al. Pentraxin-3, Troponin T, N-Terminal Pro-B-Type Natriuretic Peptide in Septic Patients. Shock. 2020. PMID: 32941388. doi:10.1097/SHK.0000000000001543

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。